139 related articles for article (PubMed ID: 26230589)
1. Standardized Molecular Monitoring for Variant BCR-ABL1 Transcripts in Chronic Myeloid Leukemia.
Langabeer SE
Arch Pathol Lab Med; 2015 Aug; 139(8):969. PubMed ID: 26230589
[No Abstract] [Full Text] [Related]
2. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.
Press RD; Kamel-Reid S; Ang D
J Mol Diagn; 2013 Sep; 15(5):565-76. PubMed ID: 23810242
[TBL] [Abstract][Full Text] [Related]
3. Absolute quantification of BCR-ABL1 fusion transcripts in pediatric chronic myeloid leukemia.
Tang Y; Wei X; Chen J; Du Y; Chu H; Mao L; Chen J; Xu Q; Tang J; Shen S; Mao M
Leuk Lymphoma; 2016 Sep; 57(9):2216-8. PubMed ID: 27095369
[No Abstract] [Full Text] [Related]
4. Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.
Arora R; Press RD
Leuk Lymphoma; 2017 Jan; 58(1):8-16. PubMed ID: 27412040
[TBL] [Abstract][Full Text] [Related]
5. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
Beránek M; Voglová J; Sýkorová A; Belada D; Bláha M
Cas Lek Cesk; 2006; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
[TBL] [Abstract][Full Text] [Related]
6. Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR.
Jennings LJ; George D; Czech J; Yu M; Joseph L
J Mol Diagn; 2014 Mar; 16(2):174-9. PubMed ID: 24389534
[TBL] [Abstract][Full Text] [Related]
7. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
Snyder DS; McMahon R; Cohen SR; Slovak ML
Am J Hematol; 2004 Feb; 75(2):92-5. PubMed ID: 14755375
[TBL] [Abstract][Full Text] [Related]
9. Frequency and spectrum of atypical BCR-ABL1 transcripts in chronic myeloid leukemia.
Kearney L; Crampe M; Langabeer SE
Exp Oncol; 2020 Mar; 42(1):78-79. PubMed ID: 32231188
[No Abstract] [Full Text] [Related]
10. Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring.
Crampe M; Haslam K; Kelly J; Conneally E; Langabeer SE
Hematol Oncol Stem Cell Ther; 2017 Jun; 10(2):85-88. PubMed ID: 27013275
[TBL] [Abstract][Full Text] [Related]
11. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.
Luu MH; Press RD
Expert Rev Mol Diagn; 2013 Sep; 13(7):749-62. PubMed ID: 24063401
[TBL] [Abstract][Full Text] [Related]
13. Molecular Response of e19a2 BCR-ABL1 Chronic Myeloid Leukemia With Double Philadelphia Chromosome to Dasatinib.
Ikeda K; Harada-Shirado K; Matsumoto H; Noji H; Ogawa K; Takeishi Y
J Clin Oncol; 2016 May; 34(14):e130-3. PubMed ID: 24752059
[No Abstract] [Full Text] [Related]
14. Comment on: Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.
Crampe M; Langabeer SE
Mol Diagn Ther; 2015 Aug; 19(4):251-2. PubMed ID: 26224625
[No Abstract] [Full Text] [Related]
15. e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia.
Roti G; La Starza R; Gorello P; Gottardi E; Crescenzi B; Martelli MF; Mecucci C
Haematologica; 2005 Aug; 90(8):1139-41. PubMed ID: 16079118
[TBL] [Abstract][Full Text] [Related]
16. Real-time quantification for BCR-ABL transcripts in chronic myeloid leukaemia patients in UKMMC, Malaysia.
Wong FL; Hamidah NH; Hawa AA; Nurul AN; Leong CF; Saw F; Ainoon O
Malays J Pathol; 2011 Dec; 33(2):107-12. PubMed ID: 22299211
[TBL] [Abstract][Full Text] [Related]
17. Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.
Mattarucchi E; Pallotti F; Casalone R
Mol Diagn Ther; 2015 Jun; 19(3):139-40. PubMed ID: 25855586
[No Abstract] [Full Text] [Related]
18. Authors' Reply to Crampe and Langabeer: Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.
Mattarucchi E; Pallotti F; Casalone R
Mol Diagn Ther; 2015 Aug; 19(4):253-4. PubMed ID: 26224626
[No Abstract] [Full Text] [Related]
19. Chronic Myeloid Leukemia With Rare Variant b2a3 (e13a3) BCR-ABL1 Fusion.
Ha J; Cheong JW; Shin S; Lee ST; Choi JR
Ann Lab Med; 2016 May; 36(3):287-9. PubMed ID: 26915625
[No Abstract] [Full Text] [Related]
20. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
Ross DM; Branford S; Seymour JF; Schwarer AP; Arthur C; Bartley PA; Slader C; Field C; Dang P; Filshie RJ; Mills AK; Grigg AP; Melo JV; Hughes TP
Leukemia; 2010 Oct; 24(10):1719-24. PubMed ID: 20811403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
